Thomas Smith Analyst PerformanceSenior Managing Director, Biotechnology Analyst at Leerink PartnersThomas Smith is a stock analyst at Leerink Partners focused in the healthcare sector, covering 20 publicly traded companies. Over the past year, Thomas Smith has issued 16 stock ratings, including and buy recommendations. While full access to Thomas Smith's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Thomas Smith's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings24 Last 6 YearsBuy Recommendations83.33% 20 Buy RatingsCompanies Covered20 Unique Companies Ratings Distribution24RatingsDistribution of strong buy, buy, hold, and sell ratings by Thomas Smith.RatingPercentageCount Strong Buy0.0%0 ratings Buy83.3%20 ratings Hold16.7%4 ratings Sell0.0%0 ratingsOut of 24 total stock ratings issued by Thomas Smith at Leerink Partners, the majority (83.3%) have been Buy recommendations, followed by 16.7% Hold.Best & Worst CallsBest Call0000.0%MLTXAug 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%CNTBApr 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ95.0% of companies on NASDAQ19 companiesNYSE5.0% of companies on NYSE1 companyThomas Smith, an analyst at Leerink Partners, currently covers 20 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare19 companies95.0%Miscellaneous1 company5.0%Thomas Smith of Leerink Partners specializes in stock coverage within the Healthcare sector, with additional focus on companies.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY16 companies80.0%PHARMACEUTICALS2 companies10.0%Miscellaneous1 company5.0%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC1 company5.0% Thomas Smith's Ratings History at Leerink Partners Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCLDXCelldex Therapeutics9/23/2026Boost Price Target$33.51$88.00Outperform$0.0000.00% ROIEVMNEvommune9/9/2026Lower Price Target$10.98$22.00Outperform$0.0000.00% ROIATTOAttovia Therapeutics8/31/2026Initiated Coverage$20.70$52.00Outperform$0.0000.00% ROIAVTXAvalo Therapeutics7/6/2026Initiated Coverage$18.84$38.00Outperform$0.0000.00% ROIMLTXMoonLake Immunotherapeutics7/1/2026Boost Price Target$19.84$29.00Outperform$0.0000.00% ROIABVXAbivax6/30/2026Boost Price Target$132.71$148.00Outperform$0.0000.00% ROIALTAltimmune6/22/2026Initiated Coverage$3.00$10.00Outperform$0.0000.00% ROISABSSAB Biotherapeutics6/15/2026Boost Price Target$3.33$12.00Outperform$0.0000.00% ROIXFORX4 Pharmaceuticals6/2/2026Initiated Coverage$4.11$12.00Outperform$0.0000.00% ROIEQEquillium5/28/2026Upgrade$2.63$6.00Outperform$0.0000.00% ROISYRESpyre Therapeutics4/13/2026Boost Price Target$63.06$106.00Outperform$0.0000.00% ROIAGMBAgomAb Therapeutics3/3/2026Initiated Coverage$16.21$36.00Outperform$0.0000.00% ROIIVAInventiva1/12/2026Initiated Coverage$4.83$12.00Outperform$0.0000.00% ROIALMSAlumis1/6/2026Boost Price Target$16.23$32.00Outperform$0.0000.00% ROIEVMNEvommune12/1/2025Initiated Coverage$20.71$42.00Outperform$0.0000.00% ROIRAPTRapt Therapeutics9/26/2025Upgrade$24.45$37.00Outperform$0.0000.00% ROIABVXAbivax7/23/2025Set Price Target$65.45$74.00Outperform$000.0000.00% ROIEQEquillium3/28/2025Reiterated Rating$0.49$1.00Market Perform$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageB. Riley FinancialUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
